 "Cadila Healthcare up 7% on USFDA approval for antipsychotic drug")
Cadila Healthcare has moved higher by 7% to Rs 496 on BSE in intra-day trade after the drug maker announced that the Zydus Cadila received final approval from the US health regulator to market antipsychotic Ziprasidone Hydrochloride capsules.
Ziprasidone, an antipsychotic medication, is used to treat schizophrenia and the manic symptoms of bipolar disorder (manic depression).
“Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Ziprasidone Hydrochloride Capsules in strength of 20 mg, 40 mg, 60 mg and 80 mg,” Cadila Healthcare said in a press release.
The drug will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad, it added.
The group now has more than 140 approvals and has so far filed over 300 ANDs since the commencement of the filing process in FY2003-04, the company said.
At 11:06 am; the stock was up 6% at Rs 491 on BSE, as compared to 0.01% decline in the S&P BSE Sensex. A combined 1.87 million shares changed hands on the counter on BSE and NSE so far.
Ziprasidone, an antipsychotic medication, is used to treat schizophrenia and the manic symptoms of bipolar disorder (manic depression).
“Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Ziprasidone Hydrochloride Capsules in strength of 20 mg, 40 mg, 60 mg and 80 mg,” Cadila Healthcare said in a press release.
The drug will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad, it added.
The group now has more than 140 approvals and has so far filed over 300 ANDs since the commencement of the filing process in FY2003-04, the company said.
At 11:06 am; the stock was up 6% at Rs 491 on BSE, as compared to 0.01% decline in the S&P BSE Sensex. A combined 1.87 million shares changed hands on the counter on BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%